<DOC>
	<DOCNO>NCT01533298</DOCNO>
	<brief_summary>The purpose study compare safety efficacy CombiflexOmega peri comparison SmofKabiven peripheral postoperative patient require parenteral nutrition .</brief_summary>
	<brief_title>A Safety , Efficacy Study CombiflexOmega Peri Versus SmofKabiven Peripheral Patients With Parenteral Nutrition</brief_title>
	<detailed_description />
	<criteria>Patients age 20 old Patients expect require PN 3 day Patients voluntarily sign consent form Patients expect difficult survive 3 day Pregnant breastfeed woman BMI &gt; 30 kg/m2 Patients severe blood coagulation disorder Patients congenital amino acid metabolism disorder Patients acute shock Patients uncontrollable diabetes mellitus Patients hemophage syndrome Patients hypopotassemia ( K &lt; 3.0mEq/L ) Patients history myocardial infarction Patients report follow laboratory value fast TG &gt; 250mg/dl , TC &gt; 300mg/dl ALT/AST ≥ 2×ULN , Bilirubin ≥ 3mg/dl ( Exception : patient periampullary carcinoma include biliary tract pancreas ) Creatinine ≥1.5mg/dl Ca &gt; 11.2mg/dl , Na ≥ 145mEq/L , Mg ≥ 2.1mEq/L , K ≥ 5.5mEq/L Patients hypersensitivity peanut , fish , soy , egg protein , investigational drug Patients history drug alcohol abuse General contraindication infusion therapy : acute pulmonary oedema , hyperhydration , cardiac decompensation Patients unstable condition Patients difficult peripheral intravenous Patients parenteral nutrition within 7 day prior start trial Participation another clinical study investigational drug investigational medical device within 28 day prior start study Patients judge unsuitable trial investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>